You are here:
Supplement Manufacturing — Pharmaceutical Grade
Last Updated:February 28, 2026
About This Investor
JP-B-201
With roots in Japan, they are currently screening targets across Indonesia, Malaysia, India. Sales of over 1 billion yen Stable operating profit Minority investment desired. Key target profile: Pharmaceutical (supplement) manufacturing and sales. The primary M&A purpose is Expand existing businesses overseas. Budget guidance is $6.54M – $13.1M. Reach out to us to share a…
Pharmaceutical Manufacturing (Supplements)
India, Indonesia, Malaysia
Overseas Expansion
$6.54M - $13.1M
Minority preferred | Revenue ≥ USD 6.5M | Stable op profit
Request Full Investor Profile
Similar Investors
JP-B-430
They are currently building a shortlist and welcome relevant introductions.
IT Hardware / Security
ASEAN, Indonesia, Malaysia, Philippines, Vietnam
Strategic Expansion
$654K - $6.54M
Minority / Majority / 100%
JP-B-335
Indicative ticket size is $6.54M – $32.7M, depending on fit
Food Manufacturing (Dairy)
ASEAN, East Asia, Europe, Oceania
Strategic Expansion
$6.54M - $32.7M
Majority preferred | Minority possible
JP-B-150
Budget guidance is $19.6M – $65.4M. From Japan, they are
Chemicals
Europe, Worldwide
Overseas Expansion
$19.6M - $65.4M
Majority / 100% | EBITDA ≥ USD 6.5M | Revenue ≥ USD 19.6M